Topical corticosteroids in atopic dermatitis and the risk of glaucoma and cataracts

• Published in: Journal of the American Academy of Dermatology 2011-02, Vol.64 (2), p.275-281
• Main Authors: Haeck, Inge M., MD, PhD, Rouwen, Ton J., MD, PhD, Timmer-de Mik, Linda, MD, de Bruin-Weller, Marjolein S., MD, PhD, Bruijnzeel-Koomen, Carla A., MD, PhD
• Format: Article
• Language: English
• Subjects: Administration, Topical; Adrenal Cortex Hormones - adverse effects; Adult; Aged; Allergic diseases; atopic dermatitis; Biological and medical sciences; cataract; Cataract - chemically induced; Dermatitis, Atopic - drug therapy; Dermatology; Eyelids; Female; glaucoma; Glaucoma - chemically induced; Glaucoma and intraocular pressure; Humans; Immunopathology; Male; Medical sciences; Middle Aged; Ophthalmology; Retrospective Studies; Skin allergic diseases. Stinging insect allergies; topical corticosteroids; Triamcinolone Acetonide - adverse effects
• ISSN: 0190-9622; 1097-6787
• DOI: 10.1016/j.jaad.2010.01.035

Introduction There is concern about the development of glaucoma and cataracts associated with topical corticosteroid use in patients with atopic dermatitis (AD). Objective We evaluated glaucoma and cataract development in patients with AD to determine whether they are associated with the cumulative dose of topical steroids and the use of topical corticosteroids on the eyelids and periorbital region. Methods In all, 88 patients with AD were recruited from the University Medical Centre Utrecht. Patients were interviewed and completed a questionnaire assessing different factors such as AD involvement of eyelids and periorbital skin. The use of corticosteroids in previous years was obtained from pharmacy records. A complete ophthalmologic examination was performed for the presence of glaucoma and cataracts. Results Of the 88 patients (41 men and 47 women), with an average age of 37.2 ± 14.3 years (mean ± SD), one patient had transient ocular hypertension and one patient had optic disc cupping without any glaucomatous defects in his visual field. Seven patients were given the diagnosis of cataracts (one AD-related, two corticosteroid-induced, and 4 age-related). Both patients with corticosteroid-induced cataracts had also used systemic corticosteroids. In all, 37 of the 88 patients had used topical corticosteroids (class III and IV) on the eyelids and periorbital region, with an average frequency of 3.9 days per week and 6.4 months per year for 4.8 years. Limitations Small sample size, objectiveness of patient recall about the use of topical corticosteroids on the eyelids/periorbital region, overestimation of topical corticosteroid use from pharmacy records, and lack of information on lifetime corticosteroid use were limitations. Conclusions In this retrospective study glaucoma was not seen; two patients with AD had corticosteroid-induced cataracts, which were probably caused by the use of systemic corticosteroids. The application of topical corticosteroids to the eyelids and periorbital region, even over longer periods of time, was not related to the development of glaucoma or cataracts in this study population.